MAPs 3 and 9: Fmoc-Bpg or Fmoc-Cys (0.05 mmol) were loaded on Rink-amide ChemMatrix resin (0.02 mmol) as above, followed by one O 2 Oc/Ahx and three Lys(Boc) residues to give b. Elongation and branching with Fmoc-Lys(Fmoc) and Fmoc-O 2 Oc/Fmoc-Ahx, as outlined in the scheme, led to tetravalent resin c, which was elongated with four copies of the ASNENMETM (NP 366-374 ) sequence. Aside from the Bpg residue, coupled manually, all other synthetic cycles were done in the automated mode using 2 mmol of Fmoc-amino acid and HBTU/HOBt, and 4 mmol of DIEA, in DMF, as described above. From the first branching point (Fmoc-Lys(Fmoc) onwards), double couplings were systematically performed. Once the protected sequence was assembled, the same work up described above was used to isolate the peptide material. Semipreparative RP-HPLC using a 15-30% linear gradient of B into A furnished 3 and 8 in a global 15% and 20% yield, respectively. Purification: Semipreparative RP-HPLC eluting with a 17 to 30% linear gradient of B into A over 30min (further HPLC details in Experimental). Yield: 50%. General Synthetic Protocol for Dendropeptide Intermediates: To a solution of 0.5 μmol (1 equiv.) of maleimide dendron (0.24 mg of 6 or 0.5 mg of 7) in CH 3 CN (400 µL), a solution of 1.5 equiv./maleimide group of peptide 8 or MAP 9 in 100 mM phosphate buffer, pH 7.4 (800 µL), was added. To monitor the reaction progress, aliquots of the mixture were taken for analytical HPLC and MALDI-TOF MS analysis, and when no further changes in the HPLC profile were observed (reaction times range from few minutes to 24 h, depending on the steric hindrance), the reaction was stopped by addition of glacial AcOH. The product was then isolated by preparative RP-HPLC. The target compounds (10-13) were obtained in homogeneous form (> 95%) by analytical HPLC and were satisfactorily characterized by MS (see Table S1 , Supporting Information). 
− Dendropeptide Intermediate 11 ((NP 365-374 ) 4 -Alk):
Purification: Semipreparative RP-HPLC eluting with a 15 to 50% linear gradient of B into A over 30min (further HPLC details in Experimental). Yield: 89%.
HPLC monitoring of the 7 + 8 CuAAC reaction leading to 11 at time 0. Elution by 15 to 50% linear gradient of B into A over 15min (further HPLC details in Experimental). Column: 4.6×50 mm, 3 μm C8 column (Phenomenex, Torrance, CA). Purification: Semipreparative RP-HPLC eluting with a 20 to 40% linear gradient of B into A over 30min (further HPLC details in Experimental). Yield: 41%.
HPLC monitoring of the 1 + 11 CuAAC reaction leading to 15 at 0 and 30 minutes. Elution by 20 to 40% linear gradient of B into A over 15min (further HPLC details in Experimental). Column: Column: 4.6×50 mm, 3 μm C8 column (Phenomenex, Torrance, CA).
− GDP16 ((4NP 365-374 ) 2 -Man 9 ):
Purification: Semipreparative RP-HPLC eluting with a 17 to 30% linear gradient of B into A over 30min (further HPLC details in Experimental). Yield: 35%. 
